Overcoming Challenges in Antibacterial Drug Discovery and Development

Table of Contents

• Executive Summary
  • Strategic Considerations
  • Stakeholder Implications
• Highly Mature Markets
• Drivers in Antibacterial Drug Discovery
  • Antibiotic Resistance and Different Resistance Mechanisms
  • Emerging Pathogens and Diseases
    • Community Setting
    • Hospital Settings
    • Biodefense Initiatives
• New Approaches to Discovering Antibacterial Agents
  • The Impact of Genomics
    • Successful Genomics Endeavors
    • Genomics-Driven, High-Throughput Screening
  • Novel Targets and Approaches
    • Novel Antibodies
    • Topical Antibacterial Agents
    • Quorum Sensing Antagonists
    • Peptide Deformylase (PDF) Inhibitors
    • Novel Beta-Lactams
    • Peptides and Peptide Mimetics
• Spectrum Executive Commentary: Quorum Sensing: Preventing Bacteria From Behaving Badly
  • Fatty Acid Biosynthesis Inhibitors
• Combination Therapies
  • Oxazolidinone-Quinolone Hybrid
  • Effl ux Pump Inhibitors (EPIs)
  • Beta-Lactamase Inhibitors
• Signifi cant Clinical Challenges
  • The Conundrum of Spectrum vs. Indication
  • Regulatory Hurdles
• Business Strategies
  • Drug Discovery
  • Marketing and Sales Alliances
  • Big Pharma' s Outlicensing Programs
  • Mergers & Acquisitions (M&As)
  • Strategies for Niche Markets
• Company Profi les
  • Oscient Pharmaceuticals
  • Cubist Pharmaceuticals
  • Replidyne
  • Novexel
• Outlook
  • Commercial Opportunity
  • Development Incentives
    • Diagnostic Testing Incentives
    • Regulatory Incentives
    • Financial and Legislative Incentives

Tables:

• 1. Mechanisms of Bacterial Resistance to Select Antibiotic Drug Classes
• 2. Companies Involved in Antibacterial Drug Discovery Programs: Key Products
• 3. Antibacterial Research and License Agreements, 2005-2007
• 4. Key Patent and Exclusivity Expiries of Drugs Used to Treat Bacterial Infections

Figures:

• 1. Market Tenure of Antibiotic Classes
• 2. Mechanisms of Transferring or Spreading Drug Resistance
• 3. Mechanisms of Antibiotic Drug Resistance
• 4. Development Timeline for Antibacterial Drugs
• 5. Top Worldwide Antibacterial Franchises, 2005
• 6. Blockbusters and Best-Selling Antibacterials Worldwide, 2005
• 7. Relative Size of Smaller Pharmaceutical and Biotech Companies Involved in Antibacterial Drug Development
• A. Selected Quorum-Sensing Antagonists